About this trial
The goal of this study is prospective, single-arm, non-randomized controlled trial to test the effectiveness, safety and performance of a novel dental obturation material. The main question sit answers is
1. To test the effectiveness of the Endofill device for root canal obturation up to 12-month follow-up period. 2. To test the performance of the Endofill device evaluated with periapical radiographs immediately on completion of procedure.
The participants requiring root canal treatment will be treated with obturated using Endofill material and post-treatment follow-up vistis will be conducted for 1 year. This is a single-arm study with no comparison groups.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients who agreed to participate and who have signed the informed consent.
Patients presenting with symptomatic and/or asymptomatic apical periodontitis and radiographic evidence of apical periodontitis in anterior or posterior teeth larger than 1.5 mm in diameter.
Mature tooth with closed apices.
Tooth that has never been treated with root canal therapy.
Disqualifiers
Patients who have pre-existing health or oral conditions that placed them at risk during the trial.
Patients with generalized untreated periodontal disease.
Patients with a history of analgesic intake within the past 3 days or antibiotics in the last 1 month.
Uncooperative patients.
Trial design
Single group
Treatments tested in this trial
Endofill
DeviceEndofill is intended for the permanent obturation of root canals following root canal preparation and disinfection.
Treatment groups
Trial outcomes
Primary outcomes
Effectiveness of root canal treatment using Endofill
To measure effectiveness by assessing overall healing, through rate of reduction in apical periodontitis, from baseline up to 12 months post-procedure by measuring periapical radiolucency size.
Secondary outcomes
Safety of root canal treatment using endofill
To measure safety by measuring postoperative pain from completion of the procedure up to 1 month of follow-up period (24 hours, 48 hours, 72 hours, 7 days, and 1 month). Pain is measured by VAS assessment. It consists of a line, approximately 10 cm in length, with the left side signifying no pain with a smiling face image and the right side signifying the worst pain with a frowning face image. A patient is asked to indicate his/her perceived pain intensity along a 100 mm horizontal line, and this rating is then measured from the left edge. A VAS score of 0 indicates no pain and a score of 10 indicates the highest level of pain experienced.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Lumendo AG
Lead sponsor
Avania
Collaborator